Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes.
Infection of primates by yellow fever virus (YFV) often results in severe multi-organ failure with marked histologic abnormalities. However, the role of host's immune response, particularly innate immunity, in disease process is unclear. In this study, we used a well established hamster model of yellow fever to examine the dynamic changes of cytokine expression and histopathology in the liver, spleen, kidney, and heart during the course of YFV infection. We observed that the levels of inflammatory cytokines (IFN-gamma, IL-2, TNF-alpha) in the liver were significantly reduced in the mid-stage of infection (8 days), but were elevated later (12 days). In contrast, IL-12p40 was elevated throughout the infection. The levels of IFN-gamma, IL-2, and TNF-alpha were increased in the spleen, kidney, and heart throughout the study period. For regulatory cytokines, IL-10 was significantly increased, and TGF-beta was reduced in the liver, spleen and heart in both early and mid-stages of infection, but was elevated in the kidney during the entire course of infection. In view of the pathologic changes, the observed cytokine profiles suggest that YFV has immunosuppressive effects, which contribute to liver damage in the mid-stage of infection, followed by an immunopathogenic mechanism that leads to disease progression during the late-stages of infection. Our findings support the hypothesis that organ injury by YFV is probably due to a combination of multiple factors, including direct viral injury and host innate immune responses.
Li
Guangyu
G
Department of Pathology and Center for Biodefense and Emerging Infectious Diseases, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
Duan
Tao
T
Wu
Xiaoyan
X
Tesh
Robert B
RB
Soong
Lynn
L
Xiao
Shu-Yuan
SY
Emerg Infect Dis. 2004 Sep;10(9):1578-84
15498159
J Pathol. 1978 Jul;125(3):131-8
102747
Diabetes. 2000 Nov;49(11):1801-9
11078446
Lancet Infect Dis. 2001 Aug;1(1):11-20
11871403
J Infect Dis. 2001 May 15;183(10):1431-6
11319679
J Virol. 2001 Mar;75(5):2107-18
11160715
Crit Rev Clin Lab Sci. 2004;41(4):391-427
15487593
Rev Infect Dis. 1987 Jan-Feb;9(1):165-75
3547569
Rev Med Virol. 2001 Mar-Apr;11(2):87-101
11262528
Infect Immun. 1994 Dec;62(12):5498-504
7960131
J Med Virol. 2001 Nov;65(3):561-6
11596094
J Immunol. 1992 Feb 15;148(4):1182-7
1531351
Methods. 2001 Dec;25(4):402-8
11846609
Neurology. 1996 Aug;47(2):417-24
8757014
Am J Pathol. 1928 Sep;4(5):395-406.1
19969807
Adv Virus Res. 2003;60:343-95
14689698
Vet Immunol Immunopathol. 2001 Feb 10;78(3-4):305-15
11292531
Cell Immunol. 1995 Jul;163(2):268-79
7606798
Exp Anim. 2002 Oct;51(5):447-55
12451705
Emerg Infect Dis. 2001;7(3 Suppl):565-9
11485676
Virology. 2006 Feb 5;345(1):22-30
16278000
Clin Exp Immunol. 2001 Jun;124(3):453-60
11472407
Infect Immun. 2000 Sep;68(9):5234-40
10948149
J Virol. 2004 Mar;78(6):3162-9
14990737
Trends Immunol. 2002 Apr;23(4):194-200
11923114
Adv Virus Res. 2003;61:291-315
14714435
Annu Rev Immunol. 1995;13:251-76
7612223
J Infect Dis. 2001 May 15;183(10):1437-44
11319680
J Virol. 1984 Feb;49(2):490-6
6319748
JAMA. 1996 Oct 9;276(14):1157-62
8827969
Nature. 1986 Oct 30-Nov 5;323(6091):819-22
2430188
Am J Trop Med Hyg. 2004 Sep;71(3):306-12
15381811
Infect Immun. 1998 May;66(5):2135-42
9573100